Agilus Diagnostics appoints Vijender Singh as new MD & CEO

Ceo ResignedCeo Appointed ExternalManagement Changes View source PDF Explain this filing

FORTIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.6%Reaction day

₹952.10

prior close

₹951.20

announcement price

In-mkt

timing

Nifty Midcap 150market+0.5%+0.1% vs market

Hospital peers, median of 23sector-0.1%+0.7% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty Midcap 150 and 0.7 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.3

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.6+0.5+0.1-0.1+0.7

Next day

+1.8+0.9+0.9+0.5+1.3

-0.1-0.2+0.1+0.2-0.3

-0.9-1.1+0.3-0.7-0.1

-0.7-1.2+0.5-0.7-0.0

-1.0-0.2-0.8+0.3-1.2

-0.3+0.7-1.0+1.1-1.4

15d

-0.7+2.2-2.9+4.4-5.2

-3.7+1.8-5.5-1.0-2.7

-5.9-0.7-5.3-0.2-5.7

-23.4-7.7-15.7-14.6-8.8

UpDownMarket · Nifty Midcap 150Sector · Hospital peers, median of 23Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Agilus Diagnostics, subsidiary of Fortis Healthcare, has appointed Vijender Singh as its new Managing Director and CEO effective July 20, 2026. He replaces Dr. Anand K, who resigned after nearly six years to pursue opportunities outside the company. Singh brings over 30 years of leadership experience across diagnostics and healthcare, having previously held senior roles at Dr. Lal PathLabs, Metropolis Healthcare, Healthians and most recently Diagnum Healthcare.

Likely market impact

Smooth leadership transition at diagnostics subsidiary; brings in seasoned industry veteran with strong scaling and IPO-era track record across major diagnostic chains.